ATE222109T1 - Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten - Google Patents

Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten

Info

Publication number
ATE222109T1
ATE222109T1 AT96901387T AT96901387T ATE222109T1 AT E222109 T1 ATE222109 T1 AT E222109T1 AT 96901387 T AT96901387 T AT 96901387T AT 96901387 T AT96901387 T AT 96901387T AT E222109 T1 ATE222109 T1 AT E222109T1
Authority
AT
Austria
Prior art keywords
hyperproliferative diseases
treatment
therapeutic procedure
combined therapeutic
period
Prior art date
Application number
AT96901387T
Other languages
English (en)
Inventor
Bruno Tocque
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE222109T1 publication Critical patent/ATE222109T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96901387T 1995-01-17 1996-01-12 Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten ATE222109T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
ATE222109T1 true ATE222109T1 (de) 2002-08-15

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96901387T ATE222109T1 (de) 1995-01-17 1996-01-12 Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten

Country Status (21)

Country Link
US (3) US6262032B1 (de)
EP (1) EP0800399B1 (de)
JP (3) JP4580469B2 (de)
KR (1) KR100385266B1 (de)
AT (1) ATE222109T1 (de)
AU (1) AU716364B2 (de)
BR (1) BR9606969A (de)
CA (1) CA2209771C (de)
CZ (1) CZ298710B6 (de)
DE (1) DE69622989T2 (de)
DK (1) DK0800399T3 (de)
ES (1) ES2180729T3 (de)
FI (1) FI119911B (de)
FR (1) FR2729295A1 (de)
HU (1) HU229484B1 (de)
MX (1) MX9704490A (de)
NO (1) NO325418B1 (de)
PT (1) PT800399E (de)
SI (1) SI0800399T1 (de)
SK (1) SK283989B6 (de)
WO (1) WO1996022101A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
DE60203260T2 (de) 2001-01-16 2006-02-02 Glaxo Group Ltd., Greenford Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
BRPI0411485A (pt) * 2003-06-30 2006-07-25 Univ Lausanne peptìdeo derivado de rasgap para matar seletivamente células cancerosas
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
KR100809890B1 (ko) * 2003-12-24 2008-03-06 가부시키가이샤 로코모젠 암 억제 방법
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122727T1 (de) * 1986-03-28 1995-06-15 Univ Illinois Zubereitungen und verfahren für klone, die, mit mehrfacharzneimittelresistenz assoziierte, dna- sequenzen in menschlichen zellen enthalten.
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations
JPH07507776A (ja) * 1992-05-28 1995-08-31 ゼノバ　リミテッド 癌の治療法
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
CA2144848A1 (en) * 1992-09-18 1994-03-31 H. Michael Shepard Gene therapy by retroviral vector with tumor suppressive gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
DE69622989D1 (de) 2002-09-19
SK95797A3 (en) 1997-12-10
US7884082B2 (en) 2011-02-08
WO1996022101A1 (fr) 1996-07-25
CZ226297A3 (en) 1997-10-15
SK283989B6 (sk) 2004-07-07
JP2012036201A (ja) 2012-02-23
FI973023L (fi) 1997-07-16
BR9606969A (pt) 1997-11-04
DE69622989T2 (de) 2002-12-05
NO973197D0 (no) 1997-07-09
JP4580469B2 (ja) 2010-11-10
US6262032B1 (en) 2001-07-17
EP0800399B1 (de) 2002-08-14
CZ298710B6 (cs) 2008-01-02
PT800399E (pt) 2002-12-31
SI0800399T1 (en) 2002-12-31
JP2008133291A (ja) 2008-06-12
CA2209771C (fr) 2012-01-03
KR19980701449A (ko) 1998-05-15
US20010021395A1 (en) 2001-09-13
HU229484B1 (en) 2014-01-28
FI973023A0 (fi) 1997-07-16
US20040127437A1 (en) 2004-07-01
AU716364B2 (en) 2000-02-24
JP5031921B2 (ja) 2012-09-26
NO973197L (no) 1997-07-09
AU4542996A (en) 1996-08-07
EP0800399A1 (de) 1997-10-15
US20050209177A9 (en) 2005-09-22
CA2209771A1 (fr) 1996-07-25
HUP9802423A3 (en) 2000-11-28
ES2180729T3 (es) 2003-02-16
JPH10512559A (ja) 1998-12-02
FR2729295A1 (fr) 1996-07-19
MX9704490A (es) 1997-10-31
HUP9802423A2 (hu) 1999-02-01
DK0800399T3 (da) 2002-12-02
NO325418B1 (no) 2008-04-21
FR2729295B1 (de) 1997-02-28
FI119911B (fi) 2009-05-15
KR100385266B1 (ko) 2005-09-07

Similar Documents

Publication Publication Date Title
DE69829921D1 (de) Vorrichtung zur Behandlung von Körpergewebe
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69600596D1 (de) Zweikammer-schrittmacher-anordnung zur kontinuierlichen regelung des av zeitintervalles mit dem ziel, optimierte stimulierung zur behandlung von kardiomyopathien zu erreichen
DE69307509D1 (de) Vorrichtung zur behandlung von herzfehlern
DE69836640D1 (de) Vorrichtung zur behandlung von gewebe mit mehrfach-elektroden
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
ATE222109T1 (de) Kombiniertes therapeutisches verfahren zur behandlung von hyperproliferativen krankheiten
ATE271038T1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
DE69519602D1 (de) Kugelförmige Aktivkohle zur Behandlung von Hämorrhoiden
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATA901396A (de) Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten
DE3875016D1 (de) Therapeutikum zur behandlung von aids.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE218866T1 (de) Kombinationstherapie zur behandlung von aids
DE60043648D1 (de) Medikamente zur behandlung von periodontalen erkrankungen
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
DE3280419D1 (de) Medizinisches praeparat zur behandlung von hautleiden.
DE69430807D1 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen
DE60122781D1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
ATE336282T1 (de) Katheter zur behandlung von prostaterkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
UEP Publication of translation of european patent specification

Ref document number: 0800399

Country of ref document: EP